Mucosal vaccine delivery MCQs With Answer

Mucosal Vaccine Delivery MCQs With Answer (Drug Delivery Systems – MPH 102T)

Mucosal vaccination aims to induce immune protection at the body’s portals of entry, such as the gut, nasal, and genital mucosa. For M. Pharm students, mastering mucosal immunology, barriers to delivery, adjuvant selection, and formulation strategies is essential for rational vaccine design. This MCQ set covers key concepts including the common mucosal immune system, M cells and inductive sites, SIgA biology, tolerance versus immunity, and advanced delivery systems like mucoadhesive and mucus-penetrating nanoparticles. You will also encounter practical formulation choices (enteric coatings, stabilizers, particle size), device considerations (nasal powders vs sprays), and safety learnings from clinical experience. Use these questions to deepen your understanding and connect immunological principles with pharmaceutics-driven solutions.

Q1. Which immunoglobulin is the predominant effector at mucosal surfaces and mediates “immune exclusion” of pathogens?

• Secretory IgA (dimeric IgA with secretory component)
• IgM (pentameric)
• IgG1 (monomeric)
• IgE

Correct Answer: Secretory IgA (dimeric IgA with secretory component)

Q2. The specialized epithelial cells that transcytose particulate antigens to Peyer’s patches, initiating gut mucosal immune responses, are:

• Goblet cells
• Enteroendocrine cells
• Microfold (M) cells
• Paneth cells

Correct Answer: Microfold (M) cells

Q3. Which pair correctly matches a gut-homing receptor on lymphocytes with its endothelial ligand in the intestinal mucosa?

• CCR7 — ICAM-1
• α4β7 integrin — MAdCAM-1
• αLβ2 integrin — VCAM-1
• CCR5 — E-selectin

Correct Answer: α4β7 integrin — MAdCAM-1

Q4. A key risk of oral vaccination without appropriate adjuvants or targeting is:

• Excessive Th1 polarization
• Oral tolerance leading to hyporesponsiveness
• Systemic anaphylaxis
• Autoimmune thyroiditis

Correct Answer: Oral tolerance leading to hyporesponsiveness

Q5. Which strategy most effectively mitigates gastric degradation of protein antigens intended for intestinal immune induction?

• Formulating as an aqueous solution with sucrose
• Enteric coating with Eudragit L100-55 or HPMCP
• Co-administering ethanol to precipitate pepsin
• Reducing dose to nanogram levels

Correct Answer: Enteric coating with Eudragit L100-55 or HPMCP

Q6. To preferentially release an oral vaccine in the distal ileum/colon and avoid premature small intestinal release, which polymer is most appropriate?

• Eudragit S100 (dissolves above pH ~7.0)
• Eudragit L100 (dissolves above pH ~6.0)
• Gelatin (rapid dissolution in gastric fluid)
• Hydroxypropyl cellulose (immediate release)

Correct Answer: Eudragit S100 (dissolves above pH ~7.0)

Q7. Which statement about chitosan in mucosal vaccine delivery is most accurate?

• It is an anionic polymer that repels mucus
• It is a cationic, mucoadhesive polymer that can transiently open tight junctions
• It dissolves rapidly at neutral pH, enhancing colon targeting
• It has strong endotoxin-like TLR4 agonism

Correct Answer: It is a cationic, mucoadhesive polymer that can transiently open tight junctions

Q8. Which adjuvant is inappropriate for human mucosal vaccination due to toxicity, despite strong experimental efficacy?

• Monophosphoryl lipid A (MPLA)
• Native cholera toxin (CT)
• CpG oligodeoxynucleotide
• Flagellin

Correct Answer: Native cholera toxin (CT)

Q9. For nasal spray vaccines aimed at nasal deposition (not pulmonary), which droplet size range is generally preferred?

• 1–3 µm
• 5–10 µm
• 30–100 µm
• 200–500 µm

Correct Answer: 30–100 µm

Q10. Which pairing best describes a validated M-cell targeting approach in the gut?

• Anti-ICAM-1 antibody — goblet cells
• FimH ligand — GP2 receptor on M cells
• Transferrin — TfR on Paneth cells
• RGD peptide — E-cadherin on enterocytes

Correct Answer: FimH ligand — GP2 receptor on M cells

Q11. Secretory IgA at mucosal surfaces primarily protects by:

• Potent complement activation and inflammation
• Immune exclusion by preventing pathogen adherence and neutralizing toxins
• Opsonizing for neutrophil phagocytosis via Fcγ receptors
• Mediating antibody-dependent cellular cytotoxicity via NK cells

Correct Answer: Immune exclusion by preventing pathogen adherence and neutralizing toxins

Q12. In PLGA-based microparticulate vaccines for oral delivery, which excipient helps counteract acidic microclimate and preserve antigen integrity?

• Magnesium hydroxide (Mg(OH)2)
• Sodium lauryl sulfate
• Glycerol
• Silicone oil

Correct Answer: Magnesium hydroxide (Mg(OH)2)

Q13. Which feature best promotes rapid diffusion of nanoparticles through mucus for enhanced epithelial access?

• Positive surface charge and mucoadhesion
• Hydrophobic surface with high zeta potential
• Dense, neutral hydrophilic coating (e.g., PEG) and size ~100–200 nm
• Aggregation to micron size to avoid steric hindrance

Correct Answer: Dense, neutral hydrophilic coating (e.g., PEG) and size ~100–200 nm

Q14. Which advantage is most characteristic of nasal dry powder vaccine formulations compared with liquid sprays?

• Reduced antigen dose required due to higher concentration of preservatives
• Improved thermal stability and cold-chain independence
• Greater penetration into the lower respiratory tract by design
• Elimination of device-to-device variability

Correct Answer: Improved thermal stability and cold-chain independence

Q15. Regarding induction sites, which statement is correct for human upper respiratory mucosa?

• NALT/Waldeyer’s ring structures (tonsils/adenoids) serve as inductive sites
• There are no organized lymphoid tissues in the nasopharynx
• Only diffuse lymphocytes exist without follicle-like structures
• Peyer’s patches extend into the nasal cavity

Correct Answer: NALT/Waldeyer’s ring structures (tonsils/adenoids) serve as inductive sites

Q16. Which strategy is most suitable to avoid oral tolerance and enhance gut mucosal immunogenicity of a protein vaccine?

• High-dose soluble antigen without adjuvant
• Co-delivery with a TLR agonist (e.g., CpG) and targeting to M cells
• Daily microgram dosing for several months
• Lyophilization without any stabilizers or carriers

Correct Answer: Co-delivery with a TLR agonist (e.g., CpG) and targeting to M cells

Q17. A past intranasal inactivated influenza vaccine adjuvanted with heat-labile toxin derivative was associated with which adverse event, leading to withdrawal?

• Guillain–Barré syndrome
• Bell’s palsy
• Agranulocytosis
• Severe asthma exacerbations in all age groups

Correct Answer: Bell’s palsy

Q18. Which prime–boost strategy most reliably elicits both strong systemic and mucosal antibody responses?

• Mucosal prime and mucosal boost only
• Parenteral prime followed by mucosal boost
• Parenteral prime and parenteral boost only
• Single high-dose oral administration without boost

Correct Answer: Parenteral prime followed by mucosal boost

Q19. In designing oral particulate vaccines to exploit M-cell uptake, which particle size range is commonly favored?

• 10–30 nm
• 100–500 nm
• 5–10 µm
• 50–100 µm

Correct Answer: 100–500 nm

Q20. Which statement about antibodies in the female genital tract is generally correct for humans?

• IgA greatly exceeds IgG in cervicovaginal secretions
• IgG often predominates in cervicovaginal secretions due to transudation from serum
• Only IgM is present in meaningful concentrations
• Antibodies are absent; only innate defenses operate

Correct Answer: IgG often predominates in cervicovaginal secretions due to transudation from serum

Download